303 related articles for article (PubMed ID: 34681839)
41. PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma.
Zhang Z; Wang Z; Huang K; Liu Y; Wei C; Zhou J; Zhang W; Wang Q; Liang H; Zhang A; Wang G; Zhen Y; Han L
Cancer Lett; 2019 Feb; 443():91-107. PubMed ID: 30529153
[TBL] [Abstract][Full Text] [Related]
42. Temozolomide treatment combined with AZD3463 shows synergistic effect in glioblastoma cells.
Goker Bagca B; Ozates NP; Asik A; Caglar HO; Gunduz C; Biray Avci C
Biochem Biophys Res Commun; 2020 Dec; 533(4):1497-1504. PubMed ID: 33109342
[TBL] [Abstract][Full Text] [Related]
43. Neovascularization directed by CAVIN1/CCBE1/VEGFC confers TMZ-resistance in glioblastoma.
Wang M; Xia D; Xu D; Yin Y; Xu F; Zhang B; Li K; Yang Z; Zou J
Cancer Lett; 2024 Feb; 582():216593. PubMed ID: 38092144
[TBL] [Abstract][Full Text] [Related]
44. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
45. FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51.
Zhang N; Wu X; Yang L; Xiao F; Zhang H; Zhou A; Huang Z; Huang S
Clin Cancer Res; 2012 Nov; 18(21):5961-71. PubMed ID: 22977194
[TBL] [Abstract][Full Text] [Related]
46. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
[TBL] [Abstract][Full Text] [Related]
47. Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma.
Tiek DM; Rone JD; Graham GT; Pannkuk EL; Haddad BR; Riggins RB
Sci Rep; 2018 May; 8(1):7222. PubMed ID: 29740146
[TBL] [Abstract][Full Text] [Related]
48. Decreased APE-1 by Nitroxoline Enhances Therapeutic Effect in a Temozolomide-resistant Glioblastoma: Correlation with Diffusion Weighted Imaging.
Cho HR; Kumari N; Thakur N; Vu HT; Kim H; Choi SH
Sci Rep; 2019 Nov; 9(1):16613. PubMed ID: 31719653
[TBL] [Abstract][Full Text] [Related]
49. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
[TBL] [Abstract][Full Text] [Related]
50. Lnc-TALC promotes O
Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
[TBL] [Abstract][Full Text] [Related]
51. The Heterogeneity of Tumour-Associated Macrophages Contributes to the Recurrence and Outcomes of Glioblastoma Patients.
Xuan Z; Fang L; Zhang G; Zhang X; Jiang J; Wang K; Huang P
J Mol Neurosci; 2023 Jan; 73(1):1-14. PubMed ID: 36542317
[TBL] [Abstract][Full Text] [Related]
52. Autophagy-based unconventional secretion of HMGB1 in glioblastoma promotes chemosensitivity to temozolomide through macrophage M1-like polarization.
Li Z; Fu WJ; Chen XQ; Wang S; Deng RS; Tang XP; Yang KD; Niu Q; Zhou H; Li QR; Lin Y; Liang M; Li SS; Ping YF; Liu XD; Bian XW; Yao XH
J Exp Clin Cancer Res; 2022 Feb; 41(1):74. PubMed ID: 35193644
[TBL] [Abstract][Full Text] [Related]
53. Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence.
Gilbert CA; Daou MC; Moser RP; Ross AH
Cancer Res; 2010 Sep; 70(17):6870-9. PubMed ID: 20736377
[TBL] [Abstract][Full Text] [Related]
54. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients.
Vaios EJ; Nahed BV; Muzikansky A; Fathi AT; Dietrich J
J Neurosurg; 2017 Jul; 127(1):132-138. PubMed ID: 27739940
[TBL] [Abstract][Full Text] [Related]
55. Long noncoding RNA just proximal to X-inactive specific transcript facilitates aerobic glycolysis and temozolomide chemoresistance by promoting stability of PDK1 mRNA in an m6A-dependent manner in glioblastoma multiforme cells.
Li XD; Wang MJ; Zheng JL; Wu YH; Wang X; Jiang XB
Cancer Sci; 2021 Nov; 112(11):4543-4552. PubMed ID: 34390075
[TBL] [Abstract][Full Text] [Related]
56. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma.
Yin J; Zeng A; Zhang Z; Shi Z; Yan W; You Y
EBioMedicine; 2019 Apr; 42():238-251. PubMed ID: 30917935
[TBL] [Abstract][Full Text] [Related]
57. miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma.
Li Y; Liu Y; Ren J; Deng S; Yi G; Guo M; Shu S; Zhao L; Peng Y; Qi S
J Neurooncol; 2018 Jul; 138(3):499-508. PubMed ID: 29876787
[TBL] [Abstract][Full Text] [Related]
58. MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma.
Chai Y; Wang C; Liu W; Fan Y; Zhang Y
J Neurooncol; 2019 Sep; 144(2):293-301. PubMed ID: 31236818
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of prolyl 4-hydroxylase, beta polypeptide (P4HB) attenuates temozolomide resistance in malignant glioma via the endoplasmic reticulum stress response (ERSR) pathways.
Sun S; Lee D; Ho AS; Pu JK; Zhang XQ; Lee NP; Day PJ; Lui WM; Fung CF; Leung GK
Neuro Oncol; 2013 May; 15(5):562-77. PubMed ID: 23444257
[TBL] [Abstract][Full Text] [Related]
60. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP
Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]